Alizapride

Alizapride

Systematic (IUPAC) name
N-[(1-Allylpyrrolidin-2-yl)methyl]-6-methoxy-1H-benzo[d][1,2,3]triazole-5-carboxamide
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, IM, IV
Legal status	℞ (Prescription only)
Pharmacokinetic data
Biological half-life	3 hours
Excretion	Renal
Identifiers
CAS Number	59338-93-1
ATC code	A03FA05 (WHO)
PubChem	CID 43008
DrugBank	DB01425
ChemSpider	39202
UNII	P55703ZRZY
KEGG	D07102
ChEMBL	CHEMBL290194
Chemical data
Formula	C16H21N5O2
Molar mass	315.37 g/mol
SMILES O=C(c2cc1nnnc1cc2OC)NCC3N(C\C=C)CCC3
InChI InChI=1S/C16H21N5O2/c1-3-6-21-7-4-5-11(21)10-17-16(22)12-8-13-14(19-20-18-13)9-15(12)23-2/h3,8-9,11H,1,4-7,10H2,2H3,(H,17,22)(H,18,19,20) Key:KSEYRUGYKHXGFW-UHFFFAOYSA-N
(verify)

Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.^[1]

References

1. Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol 22 (4): 316–20. doi:10.1007/bf00254238. PMID 3048762.